Jeff Fensterer presented “A Biodynamic Imaging Platform for Bladder Cancer” during the 19th Annual Future Directions in Urology Symposium on August 11, 2018 in Colorado Springs, Colorado.

How to cite: Fensterer, Jeff  “A Biodynamic Imaging Platform for Bladder Cancer” August 11, 2018. Accessed [date today].

A Biodynamic Imaging Platform for Bladder Cancer – Summary: 

Jeff Fensterer, Vice President of Marketing Strategy at Animated Dynamics, Inc., introduces a biodynamic imaging platform for bladder cancer that is currently under development. The assay could have clinical utility in selecting patients for neoadjuvant chemotherapy, as well as in treatment planning.

Predicting Response to Chemotherapy and Targeted Agents in Bladder Cancer Patients

Animated Dynamics is currently developing a biodynamic imaging platform with Doppler spectroscopy. This technology evaluates cellular motility in tumor spheroids removed from a patient in order to predict a bladder cancer patient’s response to chemotherapy and certain targeted agents. Physicians could utilize the platform to determine which bladder cancer patients should receive neoadjuvant chemotherapy and which ones should not. Additionally, the platform would help to determine the ideal regimen of drugs for individual patients receiving neoadjuvant chemotherapy.

Clinical Trial Patient Accrual

Animated Dynamics is currently running an open clinical trial for the platform. Eligible patients interested in participating can find more information here.

About Jeff Fensterer

In addition to his work for Animated Dynamics, Inc., Jeff Fensterer has held leadership positions in many pharmaceutical companies, including Interpace Diagnostics (formerly RedPath Integrated Pathology), LabCorp, Biodesix, Inc., and Strand Diagnostics/Know Error. Due to this experience, he has first-hand knowledge in the clinical utility of biodynamic imaging assays in cancer management.

About the Future Directions in Urology Symposium

The Future Directions in Urology Symposium (FDUS) is an annual collaborative meeting with a faculty consisting of the top researchers, physicians, and educators in the field of urology. During FDUS, experts provide updates on recent developments and debate innovative management approaches in genitourinary cancers and urologic conditions. Subsequently, the experts devise consensus statements in accordance with the discussions held in the meeting.

In this video, Fensterer discloses the thesis of the discussion he led during FDUS.